Cayetano Navas
Jan 12, 2026
Share
In this Newsletter, the International Coenzyme Q10 Association highlights recent studies advancing our understanding of Coenzyme Q10 biology and disease relevance. In addition to clinical insights into genetic CoQ10 deficits, neurodegeneration, statin-associated muscle toxicity, and ferroptosis, the chosen publications include basic processes of CoQ10 uptake, trafficking, and redox control. All of these results suggest to new therapeutic approaches focused on maintaining CoQ10 homeostasis and support the critical role of CoQ10 in mitochondrial function, cellular resilience, and metabolic health.
“If you know you are on the right track, if you have this inner knowledge, then nobody can turn you off… no matter what they say.” –Barbara McClintock
1.- When Statins Drain CoQ10: Mapping the Molecular Roots of Muscle Toxicity
One of the most commonly prescribed medications in the world, statins, are essential for preventing cardiovascular disease. Statin-associated muscular symptoms (SAMS), which can range from minor discomfort to severe muscle injury, affect a considerable percentage of patients despite their established benefits. Coenzyme Q10 (CoQ10), a crucial mitochondrial chemical involved in energy synthesis and antioxidant defense, is thought to be depleted in these adverse effects. The exact chemical pathways behind this relationship, however, are still unknown.
To understand the complex biochemical relationships between statin use, CoQ10 reduction, and muscle damage, researchers recently used network pharmacology and bioinformatics. The authors found 145 common genes and mapped their protein–protein interaction networks by combining gene databases associated with statins, CoQ10 insufficiency, and SAMS. Important hotspots were identified as important inflammatory and metabolic regulators, including TNF, IL6, TP53, and MAPK-related pathways. These results demonstrate how statin-induced alteration of the mevalonate pathway may make muscle tissue more vulnerable to oxidative stress, apoptotic events, inflammatory signals, and mitochondrial dysfunction.
Significantly, the research links immunological activation with compromised mitochondrial energy metabolism caused by CoQ10 depletion, establishing the TNF–MAPK signaling axis at the center of SAMS pathogenesis. Despite being computational in nature, the study highlights the need for focused experimental and clinical validation and offers a solid molecular basis supporting further interest in mitochondrial preservation techniques, such as CoQ10 supplementation.
In summary, statin-induced CoQ10 depletion may increase muscle deterioration through mitochondrial dysfunction and inflammatory TNF–MAPK signaling, providing additional molecular targets for safer lipid-lowering tactics.
references
Ganamurali N, Sabarathinam S. Network Pharmacology Insights Into Statin-Induced Coenzyme Q10 Deficiency: Lipid Metabolic Crosstalk, TNF-MAPK Signaling, and Muscle Toxicity. Lipids. 2025 Dec 9
keywords: SAMS; TNF‐MAPK signaling pathway; coenzyme Q10; network pharmacology; statins.
2.- How Cells Capture CoQ: Visualizing Uptake, Trafficking, and Mitochondrial Delivery
Since the synthesis of mitochondrial energy and redox equilibrium depend on coenzyme Q (CoQ), it is still quite unclear how cells internalize, transport, and distribute this extremely hydrophobic molecule. This study provides long-needed insight into the intracellular path of CoQ biology by introducing a potent experimental advancement that enables direct visualization of CoQ biology inside living cells.
The scientists created a clickable, slightly altered CoQ imaging probe that allows for high-resolution fluorescence tracking and closely resembles native CoQ10. Using this method, they demonstrate that exogenous CoQ enters cells via receptor-mediated endocytosis rather than freely diffusing into cells. Once inside, lysosomes are where CoQ mostly accumulates, indicating that these organelles serve as a major center for CoQ handling. Two important regulators of this route are identified by the study: NPC1, which is necessary for exporting CoQ from lysosomes toward mitochondria and other compartments, and CD36, which regulates cellular absorption at the plasma membrane.
The researchers suggest a two-step paradigm for CoQ trafficking that combines imaging, genetic knockdown, biochemical analysis, and functional assays: NPC1 controls intracellular redistribution, whereas CD36 facilitates absorption. This system directly affects mitochondrial respiration and oxidative stress resilience and is conserved across cell types and species, including cardiomyocytes and brown adipocytes. Additionally, the findings shows that CoQ distribution is much improved by lipoprotein-like nanodisk formulations, highlighting the significance of formulation in supplementing techniques.
Overall, This study changes our understanding of CoQ bioavailability and mitochondrial delivery by demonstrating that CoQ absorption is an active, lysosome-centered process regulated by CD36 and NPC1.
references
keywords: Coenzyme Q uptake; lysosomal trafficking; CD36; NPC1; imaging probe.
3.- Crossing the Brain’s Barrier: New Models to Understand CoQ10 in Neuronal Health
Coenzyme Q10 (CoQ10) is essential for cellular resilience, redox equilibrium, and mitochondrial energy production. Supplementation has demonstrated definite advantages in cardiovascular illness, but its effects on neurological conditions have been far less consistent. This thorough analysis examines a major factor contributing to this disparity: the blood–brain barrier’s (BBB) restrictive nature, which makes it difficult for CoQ10 to enter the human brain.
To investigate CoQ10 transport across the blood-brain barrier and its metabolism in neurons, the scientists look at a variety of in vitro and in vivo model systems. There is evidence that the brain absorption of CoQ10 may be overestimated in classic animal models due to the major differences in the structure and transporter expression of the human BBB. On the other hand, sophisticated human cell-based models, particularly microfluidic “BBB-on-a-chip” platforms and 3D BBB systems, might provide a more physiologically appropriate framework to study intracellular distribution and CoQ10 accessibility.
The review also emphasizes how difficult it is to handle CoQ10 once inside brain cells. CoQ10 deficiency inhibits lysosomal acidification, a process necessary for cellular waste removal and neuronal survival, increases oxidative stress, and interferes with mitochondrial respiration, according to research utilizing neural models. Crucially, supplementing with CoQ10 can partially restore these capabilities; nevertheless, substantial intracellular quantities may be necessary for complete recovery of mitochondrial enzyme activity, which raises further concerns regarding efficient delivery to the brain.
The article addresses intracellular CoQ10 trafficking processes including lipid transfer proteins like STARD7 and Saposin B, as well as relationships with vitamin E and selenium metabolism, in addition to BBB transport. All these findings highlight the fact that effective neurological uses of CoQ10 depend on transport, formulation, and cellular environment in addition to supplementing dose.
In summary, this review demonstrates that unlocking CoQ10’s therapeutic potential in neurological diseases requires an understanding of how it operates inside neurons and crosses the blood-brain barrier.
references
keywords: coenzyme Q10; vitamin E; selenium; blood–brain barrier; 2D and 3D model systems; intranasal; STARD7
4.- When CoQ10 Is Missing: Ferroptosis as a Hidden Driver of Cellular Damage
An uncommon mitochondrial condition known as primary Coenzyme Q10 (CoQ10) insufficiency is typically linked to reduced energy generation and oxidative stress. This new research, however, highlights a largely overlooked effect of CoQ10 loss: a significant susceptibility to ferroptosis, a controlled type of cell death caused by iron-dependent lipid peroxidation.
The researchers show a significant imbalance in lipid redox homeostasis in CoQ10-depleted cells using cellular models with genetically verified primary CoQ10 deficiency. These cells exhibit decreased ability to detoxify lipid peroxides and accumulate oxidized membrane lipids even in baseline circumstances. CoQ10 is an essential endogenous defense against ferroptosis, as evidenced by the quick cell death of CoQ10-deficient cells when exposed to ferroptotic triggers.
The FSP1–CoQ10 antioxidant system, a recently discovered route that functions independently of glutathione and GPX4, is mechanistically linked to this sensitivity. Reduced CoQ10 is a potent lipid radical scavenger at cellular membranes in healthy cells. This barrier breaks down with CoQ10 deficiency, enabling iron-catalyzed lipid peroxidation to spread unchecked. Crucially, the specificity of this death pathway was confirmed by the capacity of lipid antioxidants and ferroptosis inhibitors to restore cell viability.
These results place CoQ10 as a key regulator of membrane integrity and cell survival, extending its biological significance beyond mitochondrial respiration. Additionally, ferroptosis may be a factor in tissue destruction in CoQ10 deficiency illnesses, according to the study, providing new mechanistic understanding and possible therapeutic targets.
The results of this study show that primary CoQ10 deficiency weakens cellular defenses against ferroptosis, revealing lipid peroxidation–driven cell death as a key pathogenic mechanism.
references
Watanabe C, Miyauchi A, Aoki S, Watanabe M, Jimbo EF, Miyama Y, Kitayama H, Uno Y, Watanabe K, Hattori Y, Yotsumoto Y, Onuki T, Sugiyama Y, Ichimoto K, Yatsuka Y, Okazaki Y, Imasawa T, Murayama K, Ohtake A, Yamagata T, Osaka H. Ferroptosis susceptibility in primary coenzyme Q10 deficiency: Cellular insights from patient fibroblasts and clinical course of six individuals. Brain Dev. 2025 Dec 29
keywords: Coenzyme Q(10); Ferroptosis; Ferroptosis suppressor protein 1 (FSP1); Mitochondrial disease; Primary coenzyme Q(10) deficiency.
5.-When CoQ10 Deficiency Strikes the Nervous System: New Insights From COQ5 Mutations
The term “primary Coenzyme Q10” (CoQ10) deficiency refers to an increasing number of uncommon hereditary illnesses with a wide range of clinical manifestations. By reporting two siblings with a severe, early-onset neurological phenotype, this latest work broadens the clinical and molecular range of COQ5-related CoQ10 insufficiency and highlights both the diagnostic difficulties and treatment options connected to this disorder.
Developmental delay, hypotonia, ataxia, seizures, and loss of learned skills were among the symptoms of the affected siblings’ progressive neurological decline. Pathogenic variations in the COQ5 gene, which codes for an essential enzyme in the CoQ10 biosynthesis pathway, were found by thorough genomic analysis. Biochemical analyses supported the mutation’s causative role by confirming decreased CoQ10 levels and compromised mitochondrial activity. Significantly, the neurological symptoms are more severe than in COQ5 instances that have been previously documented, highlighting the disorder’s growing phenotypic heterogeneity.
The study’s main clinical takeaway is that early CoQ10 supplementation may be beneficial. Treatment resulted in partial clinical stability after diagnosis, indicating that early intervention may halt the progression of the disease, even in severe neurological manifestations. In children with unexplained neurodegeneration, the authors stress the significance of taking primary CoQ10 insufficiency into account, especially when symptoms are progressive and multisystemic. This work highlights the need for increased awareness of curable mitochondrial illnesses and the importance of genetic testing in directing focused therapy by fusing thorough clinical characterization with molecular and biochemical investigation.
Overall, this work highlights the significance of early detection and CoQ10 supplementation by showing that COQ5 mutations might result in severe neurodegeneration in children.
references
keywords: Coenzyme Q10; mitochondrial dysfunction; inflammatory bowel disease; antioxidant therapy; electron transport chain.
